Chymoral Forte: Clinical Information
Chymoral Forte (trypsin-chymotrypsin combination) is an oral proteolytic enzyme preparation indicated for managing inflammation and promoting tissue repair following acute injuries, surgical wounds, and burns, with typical dosing of 1-2 tablets three times daily.
Indications
Based on the available evidence, Chymoral Forte has demonstrated efficacy in:
- Post-surgical wound healing - particularly after orthopedic procedures 1
- Burn injury management - to modulate inflammatory response 2, 3
- Acute tissue injury - including traumatic wounds, fractures 4
- Inflammatory conditions - though evidence for lumbar disc prolapse is limited 5
The mechanism involves degradation of damaged cells and necrotic material, inactivation of inflammatory mediators, and reduction of edema and pain 4.
Dosing and Administration
According to FDA labeling 6:
Adults and children ≥12 years:
- As anti-inflammatory/relaxant: 1-2 tablets three times daily with water
- For occasional sleeplessness: 1-3 tablets 30-60 minutes before bedtime
Children 6-12 years:
- As anti-inflammatory/relaxant: 1 tablet three times daily with water
- For occasional sleeplessness: 1-2 tablets 30-60 minutes before bedtime
The preparation should be taken orally with adequate water. Clinical studies have used this formulation for 7-10 days post-injury or surgery 1.
Clinical Efficacy
In a randomized clinical trial comparing three enzyme preparations, Chymoral Forte demonstrated 1:
- Superior reduction in erythema (from 3.44 on day 3 to 1.16 on day 10, p<0.01)
- Better resolution of inflammatory symptoms including local irritation, wound discharge, edema, induration, and tenderness compared to serratiopeptidase and trypsin-bromelain-rutoside combinations
- Significant pain reduction on VAS scale (p<0.01)
- 88% good-to-excellent efficacy rating by physicians
In burn patients, trypsin-chymotrypsin modulated cytokine levels (IL-1β and IL-6), with significant decreases observed by days 7-10 post-burn 2. The preparation also influenced acute-phase proteins (C-reactive protein, α1-antitrypsin, α2-macroglobulin), demonstrating anti-inflammatory activity 3.
Contraindications and Precautions
Per FDA labeling 6:
- Pregnancy and breastfeeding: Consult physician before use
- Persistent symptoms: If symptoms continue beyond 7 days, seek medical evaluation
- Pediatric safety: Keep out of reach of children
- Overdose: Contact Poison Control Center immediately
The product should not be used if the tamper band is broken or missing 6.
Side Effects
The available evidence does not detail specific adverse effects in the provided sources. However, clinical trials reported 1:
- 92% good-to-excellent tolerability rating in post-surgical patients
- No significant safety concerns noted in burn patient studies 2, 3
Standard monitoring for any signs of allergic reaction or gastrointestinal intolerance is prudent.
Clinical Considerations
Timing of therapy: Initiate treatment early after tissue injury to prevent progression to chronic wounds 4. The enzyme preparation works by facilitating the inflammatory phase of healing, which is most active in the first 7-10 days post-injury.
Duration: Most clinical evidence supports 7-10 days of therapy for acute injuries 1. Discontinue if no improvement is seen within 7 days and reassess the clinical situation 6.
Comparative effectiveness: Chymoral Forte appears superior to serratiopeptidase and trypsin-bromelain-rutoside combinations for post-surgical inflammation 1, though the evidence base for lumbar disc prolapse is weak 5.